journal article·2026-02Open access

Reprogramming Immunogenicity of Iron Oxide Nanoparticles through Sulfated Glycan Presentation

Negin Pournoori, Heela Sarlus, Dick J. Sjöström, Rohith Pavan Parvathaneni, Oommen P. Varghese, Vesa P. Hytönen, Robert A. Harris, Per H. Nilsson, Oommen P. Oommen

Small· Volume 22· Issue 11

Abstract

ABSTRACT Heparin (HP) and dextran sulfate (DS) are well‐known for their anti‐thrombotic and immunomodulatory properties; however, a direct comparison of their immunological responses when used in drug delivery applications is lacking. This study addresses this gap by evaluating the immunological behavior of superparamagnetic iron oxide nanoparticles (SPIONs) coated with HP or DS in human whole blood, primary immune cells, endothelial cells, and in vivo. Both HP‐SPIONs and DS‐SPIONs effectively suppressed complement activation, as shown by reduced C3bc, C3bBbP, and TCC levels. Notably, HP‐SPIONs activated monocytes (CD11b) and endothelial cells (ICAM‐1, CD62P/E), whereas DS‐SPIONs suppressed endothelial activation. DS‐SPIONs were preferentially internalized by myeloid cells (∼50% neutrophils, ∼42% macrophages, ∼55% dendritic cells), while HP‐SPIONs showed significantly lower uptake (<25% dendritic cells, ∼5% neutrophils). DS‐SPIONs induced an immunosuppressive, pro‐healing phenotype in murine and human macrophages, whereas HP‐SPIONs drove a pro‐inflammatory, M1‐like response. In healthy mice, intravenous DS‐SPIONs elicited a modest increase in splenic immune cell populations compared to HP‐SPIONs, indicating early immune engagement. Collectively, both SPIONs attenuate complement activation, indicating high biocompatibility. Based on the early immunological responses, DS‐SPIONs display a pro‐healing immune profile suitable for regenerative drug delivery, whereas HP‐SPIONs induce pro‐inflammatory responses that may be leveraged for anticancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Immune cells in cancer · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Medicine and Health Technology Tampere University Tampere Finland

Department of Clinical Neuroscience Karolinska Institutet, Centre for Molecular Medicine, Karolinska Hospital Sweden

Linnaeus Centre for Biomaterials Chemistry Linnaeus University Kalmar Sweden

Department of Chemistry and Biomedicine Linnaeus University Kalmar Sweden

Department of Chemistry‐Ångström Laboratory, Translational Chemical Biology Group, Division of Macromolecular Chemistry Uppsala University Uppsala Sweden

Fimlab Laboratories Tampere Finland

School of Pharmacy and Pharmaceutical Sciences Cardiff University Cardiff UK

Funding

Sigrid Juséliuksen Säätiö · Opetushallitus · Vetenskapsrådet · H2020 Marie Skłodowska-Curie Actions

References (64)

Show source-provided references
1. 10.1021/acsabm.3c0119910.1021/acsabm.3c01199 ↗
2. 10.1056/NEJM19910530324220610.1056/NEJM199105303242206 ↗
3. 10.1155/2015/50715110.1155/2015/507151 ↗
4. 10.1517/13543784.17.7.102910.1517/13543784.17.7.1029 ↗
5. 10.1016/S0049-3848(10)70017-710.1016/S0049-3848(10)70017-7 ↗
6. 10.1155/2012/67673110.1155/2012/676731 ↗
7. 10.1056/NEJMcp05296710.1056/NEJMcp052967 ↗
8. 10.3390/ijms2401035510.3390/ijms24010355 ↗
9. 10.1163/15685620332238138410.1163/156856203322381384 ↗
10. Dextran Sulfate Suppresses Cell Adhesion and Cell Cycle Progression of Melanoma Cells
11. 10.1080/10717544.2022.203248210.1080/10717544.2022.2032482 ↗
12. 10.1016/j.carbpol.2013.10.06810.1016/j.carbpol.2013.10.068 ↗
13. 10.1016/j.molimm.2008.07.02410.1016/j.molimm.2008.07.024 ↗
14. 10.3727/096368916X69260910.3727/096368916X692609 ↗
15. 10.1097/TP.000000000000242510.1097/TP.0000000000002425 ↗
16. 10.1016/j.biomaterials.2004.10.01210.1016/j.biomaterials.2004.10.012 ↗
17. 10.1016/j.addr.2020.06.02510.1016/j.addr.2020.06.025 ↗
18. 10.3389/fimmu.2023.110138710.3389/fimmu.2023.1101387 ↗
19. 10.3389/fimmu.2021.68892710.3389/fimmu.2021.688927 ↗
20. 10.1039/D2TB00759B10.1039/D2TB00759B ↗
21. 10.3390/molecules2720711610.3390/molecules27207116 ↗
22. 10.1155/2018/347647610.1155/2018/3476476 ↗
23. 10.1016/j.biomaterials.2012.03.03510.1016/j.biomaterials.2012.03.035 ↗
24. 10.1088/0957-4484/18/3/03560310.1088/0957-4484/18/3/035603 ↗
25. Ferumoxtran‐10, a Superparamagnetic Iron Oxide as a Magnetic Resonance Enhancement Agent for Imaging Lymph Nodes: A Phase 2 Dose Study
26. Superparamagnetic Iron Oxide Based MRI Contrast Agents: Current Status of Clinical Application
27. 10.1016/j.biomaterials.2011.08.07010.1016/j.biomaterials.2011.08.070 ↗
28. 10.1038/srep1874610.1038/srep18746 ↗
29. 10.1039/C6NR07542H10.1039/C6NR07542H ↗
30. 10.1038/s41598-018-29705-y10.1038/s41598-018-29705-y ↗
31. 10.1016/j.scitotenv.2012.01.01210.1016/j.scitotenv.2012.01.012 ↗
32. 10.1038/s41598-018-23317-210.1038/s41598-018-23317-2 ↗
33. 10.1021/la703146y10.1021/la703146y ↗
34. 10.1016/j.btre.2016.03.00410.1016/j.btre.2016.03.004 ↗
35. 10.1016/j.elecom.2020.10686710.1016/j.elecom.2020.106867 ↗
36. 10.3762/bjnano.1.2210.3762/bjnano.1.22 ↗
37. 10.1186/s12951-023-02235-010.1186/s12951-023-02235-0 ↗
38. 10.1016/j.carbpol.2024.12246910.1016/j.carbpol.2024.122469 ↗
39. 10.1016/j.micron.2004.02.00310.1016/j.micron.2004.02.003 ↗
40. 10.1038/srep2911010.1038/srep29110 ↗
41. 10.1002/rth2.1226610.1002/rth2.12266 ↗
42. 10.1097/MOH.000000000000029710.1097/MOH.0000000000000297 ↗
43. 10.3389/fimmu.2021.60227710.3389/fimmu.2021.602277 ↗
44. 10.3389/fimmu.2020.56736510.3389/fimmu.2020.567365 ↗
45. 10.3389/fimmu.2016.0041810.3389/fimmu.2016.00418 ↗
46. 10.3390/ijms2502109110.3390/ijms25021091 ↗
47. 10.1097/MOH.000000000000078210.1097/MOH.0000000000000782 ↗
48. 10.4049/jimmunol.174.4.228010.4049/jimmunol.174.4.2280 ↗
49. 10.1083/jcb.130.6.147310.1083/jcb.130.6.1473 ↗
50. 10.1097/01.TP.0000078898.28399.0A10.1097/01.TP.0000078898.28399.0A ↗
51. 10.1002/adtp.20220000110.1002/adtp.202200001 ↗
52. 10.1016/j.carbpol.2020.11729110.1016/j.carbpol.2020.117291 ↗
53. 10.4049/jimmunol.150222010.4049/jimmunol.1502220 ↗
54. 10.4049/jimmunol.172.1.2010.4049/jimmunol.172.1.20 ↗
55. 10.1038/nri351510.1038/nri3515 ↗
56. 10.1038/s41598-018-22418-210.1038/s41598-018-22418-2 ↗
57. 10.3390/ijms2110372410.3390/ijms21103724 ↗
58. 10.1021/acsami.0c1838810.1021/acsami.0c18388 ↗
59. 10.1016/j.jim.2015.08.00110.1016/j.jim.2015.08.001 ↗
60. 10.1038/s41385-021-00474-810.1038/s41385-021-00474-8 ↗
61. 10.2147/IJN.S13645310.2147/IJN.S136453 ↗
62. 10.1111/j.1365-3083.1988.tb02353.x10.1111/j.1365-3083.1988.tb02353.x ↗
63. 10.1111/j.1365-3083.1985.tb01871.x10.1111/j.1365-3083.1985.tb01871.x ↗
64. 10.1016/j.molimm.2013.05.22110.1016/j.molimm.2013.05.221 ↗